Canada \u00b7 Retatrutide
Retatrutide in Canada: legal status, trials and user reports.
Retatrutide (“reta”) is one of the most searched weight-loss peptides in Canada. This page is non-commercial: what Health Canada says, where the trials stand, and what anonymous users report.
Health Canada's position
Retatrutide has no authorization and no DIN in the Drug Product Database. Health Canada named it in its August 2025 seizure advisory and its April 2026 advisory on unauthorized injectable peptides, and warned that "research use only" labels do not make these products legal. Authorized GLP-1 options in Canada include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), by prescription. More: are peptides legal in Canada?
What the evidence says
Retatrutide is an investigational once-weekly agonist of the GIP, GLP-1 and glucagon receptors made by Eli Lilly. In a 48-week phase 2 trial (NEJM 2023) it produced large dose-dependent weight loss; side effects were mainly gastrointestinal, with dose-related heart-rate increases and some skin-sensation changes. Phase 3 TRIUMPH trials have begun reporting results, but it is not approved anywhere. Last reviewed: October 2026.
What Retatrutide users report
- 342 published anonymous Retatrutide confessions; 57 mention at least one side effect.
- 3 mention Canada, a province or a Canadian city in the text.
- Among confessions that state a weight change in pounds, the median reported is 30 lb. Self-reported, unverified.
Most-mentioned side effects (share of Retatrutide confessions):
- Heart rate or palpitations: 6.4% (22)
- Anxiety or panic: 2.6% (9)
- Low mood or anhedonia: 2.3% (8)
- Nausea: 2% (7)
- Fatigue or exhaustion: 1.8% (6)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: Retatrutide hub.
Retatrutide trial results so far
Retatrutide is an investigational weekly injection from Eli Lilly that acts on GLP-1, GIP and glucagon receptors.
| Trial | Finding |
|---|---|
| Phase 2 obesity (48 weeks, NEJM 2023) | Up to about 24% average weight loss at the highest dose vs about 2% on placebo |
| Side effects | Mostly nausea, diarrhea, vomiting and constipation; raised heart rate |
| Phase 3 (TRIUMPH program) | Ongoing or reporting; not yet authorized anywhere |
| Canada | Not authorized; vials sold online are unauthorized |
Authorized options now: Zepbound, Wegovy, Saxenda.
Last reviewed October 15, 2026against Health Canada's Drug Product Database and NEJM and Health Canada.
Related
Frequently asked questions
- When will retatrutide be available in Canada?
- No date is known. It must finish phase 3 trials and be reviewed by Health Canada.
- Is retatrutide legal in Canada?
- No. It is not authorized by Health Canada, and Health Canada has named it in advisories about seized unauthorized injectable peptides.
- Is retatrutide approved anywhere?
- No. It is still in phase 3 development.
- What are authorized alternatives in Canada?
- Semaglutide and tirzepatide products are authorized by prescription; discuss options with a healthcare professional.
- Does this page say where to buy or how to dose?
- No. We do not publish sourcing, vendors, prices or dosing. We remove those from submissions.
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →